PAS
VRCA icon

Point72 Asia (Singapore)’s Verrica Pharmaceuticals VRCA Stock Holding History

Point72 Asia (Singapore)’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,372
Closed -$7.27K – 1267
2025
Q2 		$7.27K Buy
+1,372
New +$7.38K ﹤0.01% 807

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Point72 Asia (Singapore)'s VRCA Position: Q3 2025 in Review

Point72 Asia (Singapore) sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 1,372 shares — an estimated $7.27K sold.

Point72 Asia (Singapore) first reported a position in VRCA in Q2 2025 and held it in 1 quarter. The position peaked at $7.27K in Q2 2025. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Point72 Asia (Singapore) reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 1,372 Verrica Pharmaceuticals shares in Q3 2025, an estimated $7.27K.
  • Point72 Asia (Singapore) first reported a position in Verrica Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Verrica Pharmaceuticals position peaked at $7.27K in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.